Cite
HARVARD Citation
Tremblay, D. et al. (2020). Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leukemia & lymphoma. 61 (3), pp. 660-667. [Online].